[1] Shirota N,Saito K,Sugimoto K,et al. Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma:a pilot study. Cancer Imaging,2016,16（1）:1-6.
[2] Vitale A,Burra P,Frigo AC,et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages:a multicentre study. Hepatology,2015,62（3）:617-624.
[3] Prajapati HJ,Xing M,Spivey JR,et al. Survival,efficacy,and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR,2014,203（6）:W706-W714.
[4] Gao JJ,Shi ZY,Xia JF,et al. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol,2015,21（42）:12059-12070.
[5] Duffy AG,Ulahannan SV,Cao L,et al. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United Eur Gastroenterol,2015,3（5）:453-461.
[6] Newell P,Cottam B,Savage T,et al. Circulating and intratumoral macrophages in patients with hepatocellular carcinoma:correlation with therapeutic approach. Am J Surg,2013,205（5）:534-540.
[7] Abd Elrazek AE,Bilasy SE,Elbanna AE,et al. Prior to the oral therapy,what do we know about HCV-4 in Egypt:a randomized survey of prevalence and risks using data mining computed analysis. Medicine （Baltimore）,2014,93（28）:1-7.
[8] Hao JF,Zhang LW,Bai JX, et al. Incidence,risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma:a prospective cohort study. Indian J Cancer,2015,51（Suppl 2）:e3-e8.
[9] Brozzetti S,Bezzi M,De Sanctis GM,et al. Elderly and very elderly patients with hepatocellular carcinoma. Strategy for a first line treatment. Ann Ital Chir,2014,85（2）:120-128.
[10] Golfieri R,Bilbao JI,Carpanese L,et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Hepatology,2013,59（4）:753-761.
[11] Chen J,Zhou C,Long Y,et al. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma:a propensity score matching study. Tumour Biol,2015,36（1）:183-191.
[12] 张明娟,刘佳,向晓星,等. TACE联合索拉非尼治疗晚期肝癌的Meta分析. 中华肿瘤防治杂志,2015,22（2）:148-160.
[13] Cheng AL,Guan Z,Chen Z,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer,2012,48（10）:1452-1465.
[14] Iavarone M,Cabibbo G,Biolato M,et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology,2015,62（3）:784-791. |
